



Propus di	•	Commissioner for Patents, Box United States Patent and Trademark C Washington, D.C. 2
U.S. APPLICATION NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
09/857460		R 49619
03/03/400	HEOEK .	INTERNATIONAL APPLICATION NO.
1		
KEIL & WEINKAUF		PCT/EP99/09545
1101 CONNECTICUT AVENUE N W WASHINGTON, DC 20036		I.A. FILING DATE PRIORITY DATE
		**
		07 DEC 99 08 DEC 98
		0 2 AUG 2001
		DATE MAILED:
	REQUIREMENTS UNDER GNATED/ELECTED OFFI	R 35 U.S.C. 371 IN THE UNITED
1. The following items have been submitted		<u> </u>
	7 CFR 1.494) an Elected Offic	
U.S. Basic National Fee.	Indication of Small En	
Copy of the international applic	ation. Translation of the inter	mational application into English.
Oath or Declaration of inventor	s(s). Translation of Article	19 amendments into English.
Copy of Article 19 amendments	6. Other:	
Priority Document.		
	xamination Report in English and its	•
Translation of Annexes to the li	nternational Preliminary Examination	Report into English.
Applicant has requested early process the indicated items in paragraph 3 below. T prior to 20 or 30 months from the priority do U.S. Basic National Fee.	he Basic National Fee and the copy of	of the international application must be filed
3. The following items MUST be furnished acceptance under 35 U.S.C. 371:	within the period set forth below in	order to complete the requirements for
•	into English. A processing fee will	be required if submitted
later than the appropriate 2	20 or 30 months from the priority da	te.
	defective for the reasons indicated on	the attached Notice of Defective
Translation.	a . a . a . a	
·	the translation of the application and	
appropriate 20 or 30 month	hs from the priority date (37 CFR 1.	492(1)). 1.497(a) and (b), properly identifying
the application (preferably	by the International application num	ber and international filing date). A te 20 or 30 months from the priority
	ation does not comply with 37 CFR 12 CT/DO/EO/917.	1.497(a) and (b) for the reasons
d. Surcharge for providing the o	oath or declaration later than the appr	ropriate 20 or 30 months from the
priority date (37 CFR 1.49		
4. Additional claim fees of \$	mit the additional claim fees or cance	including any required multiple dependent of the additional claims for which fees are
5. [N] Applicant has not submitted the requir PCT/DO/EO/920.	ed sequence listing pursuant to 37 Cl	FR 1.821-1.825. See attached
ALL OF THE ITEMS SET FORTH IN 3(MONTHS FROM THE DATE OF THIS N THE PRIORITY DATE FOR THE APPL RESPOND WILL RESULT IN ABANDO	NOTICE OR BY 22 OR 32 MONT ICATION, WHICHEVER IS LAT	HS (where 37 CFR 1.495 applies) FROM
The time period set above may be extended be 1.136(a).	by filing a petition and fee for extensi	ion of time under the provisions of 37 CFR
6. If box 3a or 3c is checked, a translation of Annexes will be cancelled. A processing fee 7. The Article 19 amendments are cancel or 30 (37 CFR 1.495(d)) months from the processing fro	will be required if submitted later the led since a translation was not provide	an 20 or 30 months from the priority date.
Applicant is reminded that any communication address given in the heading and include the		
A conv of this w.	otice MUST be returned w	ith this response
Enclosed: PCT/DO/EO/917	X Notice of Defective Translation X PCT/DO/EO/920	un mus response.
LI: 10-0/3	Barb	ara A. Campbell

FORM PCT/DO/EO/905 (March 2001)

Telephone: 703-305-3631

Commissioner for Patents, Box PCT United States Patent and Trademark Office

U.S. APPLICATION NO.	:	FIRST NAMED APPLICAL	, זא	ATTY, DOCKET NO.	
09/857480		HEGER	R	49619	
		•*	INTERNA	ATIONAL APPLICATION NO.	
KEIL & WEINKAUF 1101 CONNECTICUT AVENUE N W WASHINGTON, DC 20036			PC	PCT/EP99/09545	
			I.A. FILING D	ATE PRIORITY DATE	
tura para tanàna dia kaominina			07 DEC 9	•• • • • • • • • • • • • • • • • • • • •	
			DATE MA	0 2 AUG 200	

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant has submitted papers under 35 U.S.C. 371 to enter the national stage in the United States of America. The items indicated below, however, are missing. The period within which to correct the deficiency noted below and avoid abandonment is set forth in the accompanying Notification.

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

45011(5)1	
لنا	The application fails to comply with the requirements of 37 CFR 1.821-1.825.
	This application does not contain, a "Sequence Listing" as a separate part of the
	disclosure on paper copy or compact disc, as required by 37 CFR 1.821(c).
ت	A copy of the "Sequence Listing" in computer readable format has not been submitted as equired by 37 CFR 1.821(e).
	A copy of the "Sequence Listing" in computer readable form has been submitted. The
c 3	ontent of the computer readable form, however, does not comply with the requirements of 7 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw equence Listing."
П	The computer readable form that has been filed with this application has been found to be
S	damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d). The paper copy or compact disc of the "Sequence Listing" is not the same as the
(computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
\Box (Other:
x A	T MUST PROVIDE: An initial or substitute computer readable form (CRF) of the "Sequence Listing." An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an
	amendment directing its entry into the specification.
	A statement that the contents of the paper or compact disc and the computer readable form
a	are the same and, where applicable, include no new matter, as required by 37 CFR .821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).
OR QUES	TIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE
	3) 308-4216, for Rules interpretation,
	3) 308-4212, for CRF submission help,
(70	3) 287-0200, for Patentin software help.

Barbara A. Campbell

Telephone: 703-305-3631



UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office Address: ASSISTANT COMMISSIONER FOR PATENTS Box PCT Washington, D.C. 20231

Barbara A. Campbell Telephone: 703-305-3631

ATTACHMENT TO FORM PCT/DO/EO/ U.S. APPLICATION NO.

09/857480

NOTICE OF DEFECTIVE TRANSLATION

	· · · · · · · · · · · · · · · · · · ·				
The receive	ed translation is defective because:				
	(1) The text in the drawings has not been properly translated;				
translation	(2) The number of claims in the International Application and the number of claims in the are not the same;				
transiation					
missing;	(3) The translation of the International Application is incomplete as a number of pages are				
	(4) Other.				
	(4) Outer.				

FORM PCT/DO/EO/913 (September 1996)